China Pharma Holdings (CPHI) AI Stock Analysis

• Market Cap: $5.07M
• Dividend Yield: N/A
• Average Volume (3M): 41.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: -29.64%
• EPS Growth: 73.63%
• Country: US
• Employees: 224
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 3,262,002
• 10 Day Avg. Volume: 15,303
• 30 Day Avg. Volume: 41,022
• PEG Ratio: 1.25
• Price to Book (P/B): 5.25
• Price to Sales (P/S): 8.98
• P/FCF Ratio: -53.68
• Enterprise Value/Market Cap: 2.30
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: >-0.01
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $1.50 ▼(-6.83% Downside)

The overall stock score is heavily influenced by the company's poor financial performance, characterized by persistent losses, high leverage, and inadequate cash flow. Technical analysis supports a bearish outlook, with the stock trading below key moving averages and indicators showing oversold conditions. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, further weighing down the score.

China Pharma Holdings Business Overview & Revenue Model

Company Description

China Pharma Holdings, Inc. (CPHI) is a pharmaceutical company engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products, particularly focusing on prescription drugs, over-the-counter medications, and health supplements. The company operates primarily in the Chinese market but also aims to expand its presence internationally. CPHI specializes in various therapeutic areas, including cardiovascular diseases, infectious diseases, and gastrointestinal disorders, leveraging its proprietary technologies to enhance drug formulations and delivery systems.

How the Company Makes Money

China Pharma Holdings generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications and over-the-counter drugs. The company has established partnerships with healthcare providers and distributors, allowing it to broaden its market reach and enhance sales. Key revenue streams include direct sales to hospitals and clinics, distribution agreements with pharmaceutical wholesalers, and export sales to international markets. Additionally, CPHI may benefit from government subsidies and grants aimed at promoting domestic pharmaceutical research and development, further contributing to its earnings.

China Pharma Holdings Financial Statement Overview

Summary

China Pharma Holdings faces significant financial challenges across all verticals. The income statement shows persistent losses and stagnant revenue growth. The balance sheet is burdened with high leverage and negative equity returns, while cash flow analysis reveals inadequate cash generation. The company needs to address these issues to improve financial health and stability.

Income Statement

The income statement reveals significant challenges, with negative margins across the board. The gross profit margin is deeply negative, indicating cost issues or pricing pressures. Net profit margin is also negative, reflecting ongoing losses. Revenue growth is stagnant in the TTM period, suggesting a lack of sales momentum. Overall, the company is struggling to achieve profitability.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting poor returns on shareholder investments. The equity ratio is low, suggesting limited equity buffer against liabilities. Overall, the financial stability is concerning with high leverage and negative returns.

Cash Flow

Cash flow analysis indicates severe issues, with negative free cash flow growth and low operating cash flow coverage. The free cash flow to net income ratio is negative, highlighting cash generation problems relative to losses. Overall, the cash flow situation is precarious, with insufficient cash generation to cover operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.14T	4.53M	7.01M	8.10M	9.64M	10.87M
Gross Profit	-136.06B	-1.99M	-281.08K	-493.92K	349.27K	1.95M
EBITDA	-758.62B	-1.96M	8.44K	-837.69K	230.34K	106.85K
Net Income	-785.57B	-4.74M	-3.08M	-10.22M	-3.94M	-3.16M
Balance Sheet
Total Assets	13.77M	14.89M	16.47M	17.78M	22.65M	21.12M
Cash, Cash Equivalents and Short-Term Investments	625.03K	626.88K	1.42M	2.03M	4.86M	957.65K
Total Debt	3.43M	3.59M	4.63M	8.76M	12.49M	7.43M
Total Liabilities	7.30M	7.14M	9.01M	13.49M	16.63M	13.11M
Stockholders Equity	6.46M	7.75M	7.45M	4.29M	6.02M	8.00M
Cash Flow
Free Cash Flow	70.26K	-758.08K	-711.20K	-811.51K	-687.89K	-909.57K
Operating Cash Flow	424.78K	-466.36K	-699.69K	-409.55K	-249.84K	-42.26K
Investing Cash Flow	-354.52K	-291.72K	-11.52K	-401.96K	-438.06K	-867.31K
Financing Cash Flow	-85.58K	27.35K	73.14K	-1.77M	4.60M	624.18K

China Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Negative. The current price of 1.61 is below the 20-day moving average (MA) of 1.73, below the 50-day MA of 1.80, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 37.49 is Neutral, neither overbought nor oversold. The STOCH value of 24.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPHI.

China Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UPC	51 Neutral	$2.41M	―	2.66%	―	-27.81%	―
SBFM	50 Neutral	$7.70M	-0.65	-25.65%	―	19.22%	98.73%
SNOA	47 Neutral	$6.20M	-1.53	-76.14%	―	25.02%	55.11%
EVOK	46 Neutral	$16.61M	-3.72	-152.92%	―	70.02%	82.33%
CPHI	41 Neutral	$5.07M	-1.03	-52.05%	―	-29.64%	73.63%